3 Pharma Trends for 2024: All about market access
Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.
Our products
Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.
Discover key FDA & EMA drug approvals of 2024, breakthrough innovations, and market trends. Explore what these approvals reveal about the pharma industry's future.
Discover insights from 'Market Access 2025' on overcoming HTA and drug reimbursement challenges. Learn strategies to navigate evolving market access hurdles.
Revitalized US approvals and thriving innovation are positive signs for new medicines this year. However, our Launch Readiness 2024 guide shows that cost and value remain critical to launch success.
Discover the key HTA and market access challenges in the pharma industry for 2024 and how companies can navigate them. Learn about the impact of EU's pharma review and price pressures in Germany and Japan, and get ready for EU's HTAR.
2023 New Drug Approvals: Review of New FDA and EMA Marketing Authorisations
As market access barriers proliferate, digitally enabled alignment is key to optimising new drug uptake.
Our Launch Readiness 2023 report examines the prospects and challenges for new medicines entering the market in the shadow of COVID-19.
Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.
We look at how EU drug approvals hold firm in 2022, US lags and innovation flourishes
With COVID-19 driving innovation and agility, 2022 promises another rich crop of pharma launches. Closer cost-benefit scrutiny demands carefully differentiated value.
Our 8 pharma trends for 2022 assess how new directions in the industry might lead to a more holistic conception of the value and benefit of drug innovation
US and EU drug approvals have maintained their momentum in 2021, as another innovation bounty shows the sector is finding ways to work around COVID-19.
TRiBECA Knowledge needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Notice.